Cell Therapy Market worth USD 23.9 billion by 2030

The Market Statsville Group (MSG) publishes the new report on the "Cell Therapy Market by Use-Type (Clinical-use (Therapeutic Area and Cell Type) and Research-use), by Therapy Type (Allogenic Therapies and Autologous Therapies), by Region – Global Share and Forecast to 2030". The global cell therapy market size is projected to grow USD 23.9 billion by 2030 from USD 8.1 billion in 2021, registering a CAGR of 14.5% during the forecast period. Market growth has been aided by the gradual emergence of new technologies to support the development of advanced cellular therapies. The introduction of proprietary cell lines is recognized as the primary means by which a single product can be exploited to produce a robust portfolio of candidates. For Instance, To advance their immuno-oncology product line, Immunicum, a cell-based therapy developer, uses CAR-T (Chimeric Antigen Receptor T) cell expansion, dendritic cell neoantigen presentation technology, and T-cell primers. These technologies offer low-risk investments. Companies are leveraging new technologies to assist their product development activities in expanding their product portfolio and establishing out-licensing or co-development relationships with other entities. For instance, MaxCyte has over 40 high-value cell therapy partnership programs within immune-oncology, regenerative medicine, and gene editing, including 15 clinical-stage programs.

Global Cell Therapy Market Segmentation

The overall cell therapy market has been segmented into the use-type, therapy, and region.

By Use-Type Outlook (Sales/Revenue, USD Billion, 2017-2030)

• Clinical-use
  • Therapeutic Area
    • Malignancies
    • Musculoskeletal Disorders
    • Autoimmune Disorders
    • Dermatology
    • Others
  • Cell Type
    • Stem Cell Therapies
      • BM, Blood, & Umbilical cord-derived Stem Cells
      • Adipose-derived cells
      • Others
    • Non-stem Cell Therapies
• Research-use

By Therapy Type Outlook (Sales/Revenue, USD Billion, 2017-2030)

• Allogenic Therapies
• Autologous Therapies

By Region Outlook (Sales/Revenue, USD Billion, 2017-2030)

• North America (US, Canada, Mexico)
• South America (Brazil, Argentina, Colombia, Peru, Rest of Latin America)
• Europe (Germany, Italy, France, UK, Spain, Poland, Russia, Slovenia, Slovakia, Hungary, Czech Republic, Belgium, the Netherlands, Norway, Sweden, Denmark, Rest of Europe)
• Asia Pacific (China, Japan, India, South Korea, Indonesia, Malaysia, Thailand, Vietnam, Myanmar, Cambodia, the Philippines, Singapore, Australia & New Zealand, Rest of Asia Pacific)
• The Middle East & Africa (Saudi Arabia, UAE, South Africa, Northern Africa, Rest of MEA)

Autologous therapies, by therapy type, is estimated to hold the largest market share during the forecast period

Based on therapy type, the global cell therapy market is segmented into allogeneic therapies and autologous therapies. The autologous therapies segment generated the highest revenue of 55.1% of the global cell therapy market in 2021. The autologous stem cell transplant therapies segment is anticipated to grow at the fastest CAGR during the forecast period. This can be attributed to numerous advantages associated with autologous transplants. Various advantages include use of own cells, easy availability, lower risk of life-threatening complications, no need to identify an HLA-matched donor, no risk of GVHD, no need for immunosuppressive therapy, graft failure occurs rarely, mortality is lower than 5% in most studies, and elderly patients can tolerate treatment relatively well. Moreover, autologous therapies are affordable when compared to allogeneic therapies. In addition, the high survival rate associated with this transplant type as well as the relatively high adoption rate are factors expected to boost the segment growth over the forecast period.

Don't miss out on business opportunities in Cell Therapy Market. Speak to our research analyst and gain crucial market insights that will benefit your business grow.

North America accounts for the largest market share in cell therapy market

Based on the regions, the global cell therapy market has been segmented across North America, Asia-Pacific, Europe, South America, and the Middle East & Africa. In 2021, North America accounted for the highest market share of 45.2% in the global cell therapy market and was anticipated to maintain its dominance throughout the forecast period. Major factors that can be attributed to the largest share of this region are the substantial number of centers and institutes engaged in R&D pertaining to stem cell therapy. Out of the eight leading universities that support stem cell therapy throughout the world, five are U.S.-based institutes, including Harvard Stem Cell Institute, Harvard University; Yale Stem Cell Center, Yale University; The Broad Stem Cell Research Center, University of California (UCLA); Institute for Stem Cell Biology and Regenerative Medicine, Stanford University; and Cambridge Stem Cell Institute, Cambridge University. These institutes are most likely to drive stem cell research in North American countries in the coming years. Moreover, investments made by the federal bodies for expanding stem cell therapy research in the region are projected to aid in the development of the North America market of stem cell therapy.

This research report includes a study on the development and marketing strategies, along with a study on the product portfolios and winning strategies of the leading companies operating in the cell therapy market. It also consists of the profiles of leading companies such as JCR Pharmaceuticals Co., Ltd., Castle Creek Biosciences, Inc., MEDIPOST, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., Anterogen Co., Ltd., NuVasive, Inc., Vericel Corporation, PHARMICELL Co., Ltd, Tameika Cell Technologies, Inc., Cells for Cells, and Celgene Corporation. These market players have focused on acquisitions and expansion to gain a larger market share in the cell therapy market.

Browse complete report: https://www.marketstatsville.com/cell-therapy-market

About Market Statsville Group

Market Statsville Group (MSG) is a business research and consulting platform of Statsville Consulting Private Limited, based in Oklahoma, USA. MSG is the leading market research and strategy builder with the depth and breadth of solutions that perfectly suit your every need. MSG provides solutions in a wide range of industry verticals in market sizing, analysis, and intelligent business insights. MSG has experienced research analysts who are proficient at digging deep and providing various customizable data that help you make decisions with clarity, confidence, and impact. Furthermore, Market Statsville Group already benefited more than 1,000 companies each year for their revenue planning. It helped them take their disruptions/innovations early to the market by providing them research ahead of the curve.

MSG has an entire repository of research reports on more than 1,000 niche industries, 3,000 high-growth potentials markets, 5,000 data sets, and more than 12,000 company profiles.

Contact Us:

Market Statsville Group

416, East Standsberry Street, Perkins, Oklahoma 74059, USA

USA: +1-580-205-2707 | +91 702 496 8807

Email: sales@marketstatsville.com

Web: www.marketstatsville.com